XOMA Company Profile (NASDAQ:XOMA)


XOMA logoXOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:XOMA
  • CUSIP: 98419J10
  • Web: www.xoma.com
  • Market Cap: $51.05 million
  • Outstanding Shares: 7,585,000
Average Prices:
  • 50 Day Moving Avg: $6.66
  • 200 Day Moving Avg: $5.75
  • 52 Week Range: $0.34 - $8.13
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.37
  • P/E Growth: -0.16
Sales & Book Value:
  • Annual Revenue: $1.86 million
  • Price / Sales: 27.44
  • Book Value: ($4.11) per share
  • Price / Book: -1.64
  • EBIDTA: ($51,240,000.00)
  • Net Margins: -20.10%
  • Return on Assets: -24.11%
  • Debt-to-Equity Ratio: -1.05%
  • Current Ratio: 0.98%
  • Quick Ratio: 0.98%
  • Average Volume: 141,975 shs.
  • Beta: 3.56
  • Short Ratio: 5.91

Frequently Asked Questions for XOMA (NASDAQ:XOMA)

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

How were XOMA's earnings last quarter?

XOMA Co. (NASDAQ:XOMA) announced its earnings results on Thursday, March, 16th. The company reported ($2.89) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.32) by $0.57. The firm earned $0.50 million during the quarter, compared to analyst estimates of $0.50 million. The business's revenue was down 88.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.21 earnings per share. View XOMA's Earnings History.

Where is XOMA's stock going? Where will XOMA's stock price be in 2017?

4 brokerages have issued 12 month price targets for XOMA's stock. Their predictions range from $9.00 to $9.00. On average, they expect XOMA's share price to reach $9.00 in the next year. View Analyst Ratings for XOMA.

What are analysts saying about XOMA stock?

Here are some recent quotes from research analysts about XOMA stock:

  • 1. According to Zacks Investment Research, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. " (5/9/2017)
  • 2. Cowen and Company analysts commented, "XOMA released additional data from its Phase II studies of XOMA 358 in patients." (2/1/2017)

Who are some of XOMA's key competitors?

Who owns XOMA stock?

XOMA's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.74%), Stonepine Capital Management LLC (1.17%), Geode Capital Management LLC (0.54%) and California Public Employees Retirement System (0.29%). Company insiders that own XOMA stock include Bros Advisors Lp Baker, James R Neal, John Varian, Patrick J Md Phd Scannon and Paul D Rubin. View Institutional Ownership Trends for XOMA.

Who bought XOMA stock? Who is buying XOMA stock?

XOMA's stock was acquired by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Vanguard Group Inc., California Public Employees Retirement System and Geode Capital Management LLC. View Insider Buying and Selling for XOMA.

How do I buy XOMA stock?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of XOMA stock cost?

One share of XOMA stock can currently be purchased for approximately $6.73.

MarketBeat Community Rating for XOMA (NASDAQ:XOMA)
Community Ranking:  2.6 out of 5 ( )
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  150 (Vote Underperform)
Total Votes:  315
These ratings are a survey of what our community members think about XOMA. An outperform vote indicates that you believe the stock will outperform the S&P 500 over the long term. An underperform vote indicates that you believe the stock will underperform the S&P 500.

Analyst Ratings

Consensus Ratings for XOMA (NASDAQ:XOMA) (?)
Ratings Breakdown: 4 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $9.00 (33.73% upside)

Analysts' Ratings History for XOMA (NASDAQ:XOMA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/27/2017WedbushReiterated RatingNeutral$14.00 -> $9.00HighView Rating Details
2/1/2017Cowen and CompanyReiterated RatingHoldN/AView Rating Details
11/16/2016Ladenburg Thalmann Financial ServicesReiterated RatingNeutralN/AView Rating Details
8/5/2016Jefferies Group LLCReiterated RatingHoldN/AView Rating Details
3/12/2016Piper Jaffray CompaniesReiterated RatingHoldN/AView Rating Details
3/11/2016Royal Bank of CanadaReiterated RatingSector Perform$2.00N/AView Rating Details
9/15/2015Deutsche Bank AGReiterated RatingSellN/AView Rating Details
6/29/2015Susquehanna Bancshares IncDowngradePositive -> NeutralN/AView Rating Details
(Data available from 5/28/2015 forward)


Earnings History for XOMA (NASDAQ:XOMA)
Earnings by Quarter for XOMA (NASDAQ:XOMA)
Earnings History by Quarter for XOMA (NASDAQ:XOMA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/2017Q4 2016($2.32)($2.89)$0.50 million$0.50 millionViewN/AView Earnings Details
11/9/2016Q3($2.40)($2.08)$1.29 million$0.64 millionViewN/AView Earnings Details
8/3/2016($0.12)($0.13)$0.84 million$0.40 millionViewN/AView Earnings Details
5/4/2016($0.12)($0.07)$1.17 million$3.96 millionViewN/AView Earnings Details
3/9/2016Q415($0.15)$0.21$4.01 million$48.18 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.18)$3.55 million$2.10 millionViewListenView Earnings Details
8/6/2015Q215($0.18)($0.20)$4.38 million$2.54 millionViewListenView Earnings Details
5/7/2015Q115($0.16)($0.19)$4.31 million$2.65 millionViewListenView Earnings Details
3/11/2015Q414($0.14)($0.12)$10.70 million$4.30 millionViewN/AView Earnings Details
11/6/2014Q314($0.17)($0.17)$7.00 million$5.10 millionViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.17)$5.32 million$5.97 millionViewListenView Earnings Details
5/7/2014Q114($0.17)($0.23)$7.40 million$3.41 millionViewN/AView Earnings Details
3/4/2014Q413($0.19)($0.55)$7.92 million$8.45 millionViewN/AView Earnings Details
11/7/2013Q313($0.18)($0.21)$7.87 million$6.31 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.19)($0.21)$9.30 million$7.20 millionViewN/AView Earnings Details
11/7/2012Q312($0.21)($0.39)$11.69 million$7.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for XOMA (NASDAQ:XOMA)
2017 EPS Consensus Estimate: ($2.33)
2018 EPS Consensus Estimate: ($1.54)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.65)($1.65)($1.65)
Q2 20171$0.38$0.38$0.38
Q3 20171($0.65)($0.65)($0.65)
Q4 20171($0.41)($0.41)($0.41)
Q1 20181($0.41)($0.41)($0.41)
Q2 20181($0.45)($0.45)($0.45)
Q3 20181($0.40)($0.40)($0.40)
Q4 20181($0.28)($0.28)($0.28)
(Data provided by Zacks Investment Research)


Dividend History for XOMA (NASDAQ:XOMA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for XOMA (NASDAQ:XOMA)
Insider Ownership Percentage: 3.92%
Insider Trades by Quarter for XOMA (NASDAQ:XOMA)
Institutional Ownership by Quarter for XOMA (NASDAQ:XOMA)
Insider Trades by Quarter for XOMA (NASDAQ:XOMA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/16/2017John VarianDirectorSell39,540$6.24$246,729.60View SEC Filing  
3/21/2017James R. NealVPSell5,105$5.40$27,567.00View SEC Filing  
2/1/2017James R NealVPSell195$4.52$881.40View SEC Filing  
1/9/2017James R. NealVPSell125$5.15$643.75View SEC Filing  
12/21/2016John VarianDirectorSell13,549$5.75$77,906.75View SEC Filing  
12/21/2016Patrick J Md Phd ScannonVPSell3,230$5.75$18,572.50View SEC Filing  
11/1/2016James R. NealVPSell150$5.25$787.50View SEC Filing  
10/7/2016James R. NealVPSell2,500$0.45$1,125.00View SEC Filing  
3/22/2016John VarianCEOSell81,022$0.78$63,197.16View SEC Filing  
3/22/2016Patrick J Md Phd ScannonVPSell14,785$0.78$11,532.30View SEC Filing  
3/22/2016Paul D RubinCMOSell24,194$0.78$18,871.32View SEC Filing  
2/1/2016Patrick J Md Phd ScannonVPSell8,000$1.01$8,080.00View SEC Filing  
12/28/2015Patrick J Md Phd ScannonVPSell8,000$1.37$10,960.00View SEC Filing  
11/23/2015Patrick J Md Phd ScannonVPSell8,000$1.35$10,800.00View SEC Filing  
10/26/2015Patrick J Md Phd ScannonVPSell8,000$1.04$8,320.00View SEC Filing  
7/22/2015Bros. Advisors Lp BakerInsiderSell11,000,000$1.09$11,990,000.00View SEC Filing  
7/15/2015John VarianCEOSell10,000$4.49$44,900.00View SEC Filing  
7/15/2015Paul D RubinCMOSell5,000$4.60$23,000.00View SEC Filing  
7/10/2015Paul D RubinCMOSell33,400$4.55$151,970.00View SEC Filing  
6/15/2015John VarianCEOSell10,000$3.64$36,400.00View SEC Filing  
4/15/2015John VarianCEOSell10,000$3.86$38,600.00View SEC Filing  
3/23/2015Paul D RubinCMOSell32,742$3.94$129,003.48View SEC Filing  
3/16/2015John VarianCEOSell10,000$3.72$37,200.00View SEC Filing  
2/2/2015Patrick J Md Phd ScannonVPSell5,000$3.52$17,600.00View SEC Filing  
1/15/2015John VarianCEOSell10,000$3.46$34,600.00View SEC Filing  
1/6/2015Bros. Advisors Lp BakerDirectorSell2,215,400$3.81$8,440,674.00View SEC Filing  
1/2/2015Patrick J Md Phd ScannonVPSell5,000$3.55$17,750.00View SEC Filing  
12/30/2014Bros. Advisors Lp BakerDirectorSell744,000$3.67$2,730,480.00View SEC Filing  
12/19/2014Bros. Advisors Lp BakerDirectorSell1,605,100$4.26$6,837,726.00View SEC Filing  
12/16/2014Bros. Advisors Lp BakerDirectorSell1,033,800$4.46$4,610,748.00View SEC Filing  
12/15/2014John VarianCEOSell10,000$4.49$44,900.00View SEC Filing  
12/15/2014Paul D RubinCMOSell1,600$4.63$7,408.00View SEC Filing  
12/9/2014Bros. Advisors Lp BakerDirectorSell392,353$4.62$1,812,670.86View SEC Filing  
12/4/2014Bros. Advisors Lp BakerDirectorSell2,372,206$4.79$11,362,866.74View SEC Filing  
12/1/2014Patrick J Md Phd ScannonVPSell5,000$5.51$27,550.00View SEC Filing  
11/26/2014James R NealVPSell1,678$5.67$9,514.26View SEC Filing  
11/24/2014James R NealVPSell1,032$5.03$5,190.96View SEC Filing  
11/20/2014Paul D RubinCMOSell5,000$4.55$22,750.00View SEC Filing  
11/13/2014Fred KurlandCFOSell8,773$3.89$34,126.97View SEC Filing  
11/13/2014James R NealVPSell4,387$3.89$17,065.43View SEC Filing  
11/13/2014John VarianCEOSell58,844$3.89$228,903.16View SEC Filing  
11/3/2014Patrick J Md Phd ScannonVPSell5,000$4.33$21,650.00View SEC Filing  
10/28/2014Paul D RubinCMOSell5,000$4.57$22,850.00View SEC Filing  
10/15/2014John VarianCEOSell10,000$3.87$38,700.00View SEC Filing  
10/1/2014Patrick J Md Phd ScannonVPSell5,000$4.09$20,450.00View SEC Filing  
9/15/2014John VarianCEOSell10,000$4.56$45,600.00View SEC Filing  
9/15/2014Paul D RubinCMOSell5,000$4.59$22,950.00View SEC Filing  
9/4/2014Paul D RubinCMOSell10,000$4.56$45,600.00View SEC Filing  
9/2/2014Patrick J Md Phd ScannonVPSell5,000$4.31$21,550.00View SEC Filing  
8/18/2014Paul D RubinCMOSell26,748$4.34$116,086.32View SEC Filing  
8/15/2014Fred KurlandCFOSell10,401$4.31$44,828.31View SEC Filing  
8/15/2014John VarianCEOSell64,823$4.30$278,738.90View SEC Filing  
8/15/2014Patrick J Md Phd ScannonVPSell5,871$4.31$25,304.01View SEC Filing  
8/1/2014Patrick J Md Phd ScannonVPSell5,000$3.83$19,150.00View SEC Filing  
7/15/2014John VarianCEOSell10,000$4.03$40,300.00View SEC Filing  
7/1/2014Patrick J Md Phd ScannonVPSell5,000$4.68$23,400.00View SEC Filing  
6/16/2014John VarianCEOSell10,000$4.54$45,400.00View SEC Filing  
6/16/2014Paul D RubinCMOSell11,580$4.54$52,573.20View SEC Filing  
5/28/2014Paul D RubinCMOSell1,785$4.22$7,532.70View SEC Filing  
5/15/2014John VarianCEOSell10,000$3.55$35,500.00View SEC Filing  
4/15/2014John VarianCEOSell10,000$4.06$40,600.00View SEC Filing  
3/18/2014Fred KurlandCFOSell5,915$6.32$37,382.80View SEC Filing  
3/18/2014John VarianCEOSell21,329$6.32$134,799.28View SEC Filing  
3/18/2014Patrick Md Phd ScannonVPSell3,419$6.32$21,608.08View SEC Filing  
3/18/2014Paul RubinCMOSell17,649$6.31$111,365.19View SEC Filing  
3/18/2014Thomas KleinInsiderSell30,965$6.32$195,698.80View SEC Filing  
3/17/2014John VarianCEOSell10,000$6.03$60,300.00View SEC Filing  
2/18/2014John VarianCEOSell10,000$7.55$75,500.00View SEC Filing  
2/18/2014Paul RubinCMOSell6,000$7.55$45,300.00View SEC Filing  
1/21/2014Paul RubinCMOSell6,000$8.27$49,620.00View SEC Filing  
1/15/2014John VarianCEOSell10,000$8.28$82,800.00View SEC Filing  
1/9/2014Patrick Md Phd ScannonVPSell20,000$8.00$160,000.00View SEC Filing  
12/18/2013Paul RubinCMOSell6,000$5.67$34,020.00View SEC Filing  
12/16/2013John VarianCEOSell10,000$5.44$54,400.00View SEC Filing  
12/2/2013Patrick Md Phd ScannonVPSell20,000$6.00$120,000.00View SEC Filing  
11/27/2013Paul RubinCMOSell4,696$4.54$21,319.84View SEC Filing  
11/18/2013Paul RubinCMOSell1,304$4.08$5,320.32View SEC Filing  
11/15/2013John VarianCEOSell64,932$3.95$256,481.40View SEC Filing  
10/15/2013John VarianCEOSell10,000$4.60$46,000.00View SEC Filing  
9/18/2013Paul RubinCMOSell6,000$4.53$27,180.00View SEC Filing  
9/16/2013John VarianCEOSell10,000$4.59$45,900.00View SEC Filing  
8/19/2013Bros. Advisors Lp BakerDirectorBuy2,757,791$3.62$9,983,203.42View SEC Filing  
8/19/2013Paul RubinCMOSell6,000$3.74$22,440.00View SEC Filing  
8/15/2013John VarianCEOSell61,647$3.87$238,573.89View SEC Filing  
8/14/2013Fred KurlandCFOSell7,498$3.86$28,942.28View SEC Filing  
8/14/2013Patrick Md Phd ScannonVPSell6,002$3.86$23,167.72View SEC Filing  
8/14/2013Paul RubinCMOSell10,520$3.86$40,607.20View SEC Filing  
7/18/2013Paul D RubinCMOSell6,000$4.71$28,260.00View SEC Filing  
7/15/2013John VarianCEOSell10,000$4.81$48,100.00View SEC Filing  
5/29/2013Paul D RubinCMOSell1,797$4.16$7,475.52View SEC Filing  
5/20/2013Paul D RubinCMOSell6,000$0.54$3,240.00View SEC Filing  
11/14/2012Fred KurlandCFOSell9,111$2.56$23,324.16View SEC Filing  
11/14/2012John VarianCEOSell40,587$2.56$103,902.72View SEC Filing  
11/14/2012Patrick J Md Phd ScannonEVPSell8,773$2.56$22,458.88View SEC Filing  
10/29/2012Julian BakerDirectorBuy4,722,666$3.00$14,167,998.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for XOMA (NASDAQ:XOMA)
Latest Headlines for XOMA (NASDAQ:XOMA)
americanbankingnews.com logoXOMA Co. (XOMA) Director Sells $246,729.60 in Stock
www.americanbankingnews.com - May 18 at 4:34 PM
finance.yahoo.com logoXOMA Earns $10 Million Milestone Payment as Another of its Licensed Assets Advances into Clinical Development
finance.yahoo.com - May 18 at 8:46 AM
finance.yahoo.com logoXOMA to Present New Strategic Initiatives at the UBS Global Healthcare Conference
finance.yahoo.com - May 15 at 7:52 PM
americanbankingnews.com logoResearch Analysts Offer Predictions for XOMA Co.'s Q1 2018 Earnings (XOMA)
www.americanbankingnews.com - May 15 at 9:04 AM
americanbankingnews.com logoXOMA Co. Forecasted to Earn Q2 2017 Earnings of $0.38 Per Share (XOMA)
www.americanbankingnews.com - May 12 at 7:50 AM
americanbankingnews.com logoXOMA Co. to Post Q1 2018 Earnings of ($0.45) Per Share, Wedbush Forecasts (XOMA)
www.americanbankingnews.com - May 11 at 1:30 PM
finance.yahoo.com logoXOMA Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 8:16 PM
marketbeat.com logoXoma reports 1Q loss
marketbeat.com - May 9 at 6:45 PM
americanbankingnews.com logoXOMA Co. (XOMA) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 9 at 5:02 PM
americanbankingnews.com logoSomewhat Favorable Press Coverage Very Likely to Impact XOMA (XOMA) Share Price
www.americanbankingnews.com - May 4 at 8:22 AM
americanbankingnews.com logoXOMA (XOMA) Earning Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - May 1 at 4:02 PM
americanbankingnews.com logoXOMA Co. (XOMA) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 30 at 7:33 AM
americanbankingnews.com logoPositive News Coverage Extremely Likely to Affect XOMA (XOMA) Share Price
www.americanbankingnews.com - April 28 at 8:30 AM
streetinsider.com logoForm 8-K PROCTER & GAMBLE Co For: Apr 26
www.streetinsider.com - April 26 at 10:23 PM
americanbankingnews.com logoFavorable Press Coverage Extremely Likely to Impact XOMA (XOMA) Stock Price
www.americanbankingnews.com - April 25 at 3:12 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-FelCor, Bard, Ocwen, Ocean ... - Nasdaq
www.nasdaq.com - April 25 at 8:27 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and XOMA
finance.yahoo.com - April 25 at 8:26 AM
finance.yahoo.com logoXOMA Announces Positive Results from its Phase 2 Proof-Of-Concept Study of Prolactin Inhibition
finance.yahoo.com - April 24 at 8:20 AM
finance.yahoo.com logoXOMA (XOMA) Shares March Higher, Can It Continue?
finance.yahoo.com - April 21 at 10:07 PM
seekingalpha.com logoXOMA -9.6% as Novo Nordisk cancels exclusive deal
seekingalpha.com - April 21 at 7:22 PM
americanbankingnews.com logoVery Favorable News Coverage Likely to Affect XOMA (XOMA) Stock Price
www.americanbankingnews.com - April 21 at 9:43 AM
americanbankingnews.com logoXOMA Co. (XOMA) Sees Large Increase in Short Interest
www.americanbankingnews.com - April 19 at 10:20 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE- Goldman, Cardinal Health, Xoma, Interpace - Nasdaq
www.nasdaq.com - April 19 at 8:03 AM
americanbankingnews.com logoXOMA (XOMA) Receives News Sentiment Rating of 0.16
www.americanbankingnews.com - April 18 at 12:42 PM
finance.yahoo.com logoXOMA Presents Positive Data from PTH1R Monoclonal Antibody Program
finance.yahoo.com - April 18 at 8:09 AM
americanbankingnews.com logoXOMA (XOMA) Earns News Sentiment Score of 0.12
www.americanbankingnews.com - April 14 at 8:50 AM
americanbankingnews.com logoXOMA Co. (XOMA) Earns Neutral Rating from Wedbush
www.americanbankingnews.com - March 31 at 11:53 AM
americanbankingnews.com logoXOMA Co. to Post Q1 2017 Earnings of ($1.65) Per Share, Wedbush Forecasts (XOMA)
www.americanbankingnews.com - March 29 at 10:01 AM
americanbankingnews.com logoZacks Investment Research Upgrades XOMA Co. (XOMA) to "Buy"
www.americanbankingnews.com - March 29 at 9:44 AM
americanbankingnews.com logoXOMA Co. (XOMA) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - March 29 at 8:47 AM
americanbankingnews.com logoWedbush Comments on XOMA Co.'s FY2021 Earnings (XOMA)
www.americanbankingnews.com - March 28 at 2:21 PM
americanbankingnews.com logoXOMA Co. (XOMA) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 28 at 8:41 AM
finance.yahoo.com logoXOMA to Present Preclinical Data from its PTH1R Monoclonal Antibodies Program at the American Association for Cancer Research Annual Meeting
finance.yahoo.com - March 28 at 8:09 AM
biz.yahoo.com logoXOMA CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfe
biz.yahoo.com - March 27 at 8:03 PM
americanbankingnews.com logoWedbush Reiterates Neutral Rating for XOMA Co. (XOMA)
www.americanbankingnews.com - March 27 at 4:34 PM
americanbankingnews.com logoInsider Selling: XOMA Co. (XOMA) VP Sells 5,105 Shares of Stock
www.americanbankingnews.com - March 23 at 1:35 PM
americanbankingnews.com logoXOMA Co. (XOMA) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 23 at 11:05 AM
finance.yahoo.com logoXOMA CORP Financials
finance.yahoo.com - March 23 at 9:03 AM
finance.yahoo.com logoXOMA Announces Four Presentations at the 2017 ENDO Meeting
finance.yahoo.com - March 23 at 9:03 AM
feeds.benzinga.com logoXOMA Announces Full Repayment of Hercules Technology Growth Capital Debt Obligation
feeds.benzinga.com - March 22 at 8:26 AM
finance.yahoo.com logoXoma Stock Tumbles 3.81% After Earnings Release
finance.yahoo.com - March 17 at 3:33 PM
us.rd.yahoo.com logoXOMA Reports Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 16 at 8:30 AM
biz.yahoo.com logoQ4 2016 XOMA Corp Earnings Release - Before Market Open
us.rd.yahoo.com - March 16 at 8:30 AM
biz.yahoo.com logoXOMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - March 16 at 8:30 AM
finance.yahoo.com logoXOMA to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call Focused on its New Strategic Direction on March 16, 2017
finance.yahoo.com - March 14 at 8:16 AM
biz.yahoo.com logoXOMA CORP Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 9 at 6:01 AM
biz.yahoo.com logoXOMA CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - March 6 at 8:32 AM
finance.yahoo.com logoXOMA to Present New Strategic Initiatives at the Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - February 28 at 10:54 AM
finance.yahoo.com logoXOMA Appoints Matthew Perry to its Board of Directors - Yahoo Finance
finance.yahoo.com - February 17 at 8:19 AM
biz.yahoo.com logoXOMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of Security
biz.yahoo.com - February 17 at 8:19 AM



XOMA (XOMA) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff